Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trialYunpeng Yang, Li Zhang, Jianya Zhou et al.|The Lancet Respiratory Medicine|2019Cited by 139
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA SequencingYunpeng Yang, Li Zhang, Jie Huang et al.|Journal of Thoracic Oncology|2021Cited by 44
The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancerDevalingam Mahalingam, Steffan T. Nawrocki, George M. Gill et al.|BMC Cancer|2015Cited by 19
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory <i>ALK</i> ‐positive NSCLC from a phase II studyJing Zheng, Li Zhang, Tao Wang et al.|癌症：英文版|2024Cited by 9
P-175 Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN in Combination with Gemcitabine in Patients with Advanced Pancreatic AdenocarcinomaDevalingam Mahalingam, M. Mita, Sanjay Goel et al.|Annals of Oncology|2015Cited by 8